echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 7 people in the UK have died of blood clots after being vaccinated with AstraZeneca

    7 people in the UK have died of blood clots after being vaccinated with AstraZeneca

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    7 people in the UK have died of blood clots after being vaccinated with AstraZeneca
    In the UK, 7 people have died of blood clots after vaccinated with AstraZeneca.
    7 people in the UK have died of blood clots after vaccinated with AstraZeneca.

     

    Xinhua News Agency, London, April 3 (Reporter Zhang Jiawei Jin Jing) The British Broadcasting Corporation quoted the country’s Medicines and Health Products Administration on the 3rd, saying that seven people in the country have been vaccinated with the joint research and development of AstraZeneca Pharmaceuticals and Oxford University.
    After the new crown vaccine, he developed thrombotic symptoms and died.

    The British Medicines and Health Products Administration updated the regular new crown vaccine analysis report on the 1st.
    As of March 24, the British people have received 18.
    1 million doses of AstraZeneca's new crown vaccine.
    The bureau recorded 30 cases of blood clots after vaccination.
    Symptomatic cases.
    The bureau said that it is continuing to evaluate the situation, but based on existing evidence, the benefits of vaccination against the new crown still outweigh the risks, and people should go to the relevant places to get the vaccination as soon as possible after receiving the notice.

    The latest data from the British government shows that as of April 1, 31,301,267 people in the UK have received the first dose of the new crown vaccine.
    The Medicines and Health Products Administration of the United Kingdom stated that another vaccine vaccinated in the United Kingdom was developed by Pfizer in cooperation with the German Biotech Company.
    At present, there are no reports of thrombotic symptoms after this vaccine in the United Kingdom.

    Due to concerns about the possible risk of blood clots after vaccination, Denmark, Germany, France, Italy and other countries announced the suspension of the use of AstraZeneca vaccine in mid-March.
    Subsequently, the World Health Organization stated on March 17 that given that the vaccine's anti-epidemic effect is greater than the potential risk, it is still recommended to continue vaccination.
    The European Medicines Agency's preliminary investigation results released on March 18 showed that the AstraZeneca vaccine "benefits outweigh the risks", but it does not rule out that it is related to a very small number of thrombosis cases.
    Subsequently, France, Germany and many other countries resumed vaccination of this vaccine one after another.

    aspx?id=3570" target="_blank" style="color:#ba1413">Focus on the new crown pneumonia epidemic
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.